Ebihara A, Tawara K, Oka T
Arzneimittelforschung. 1983;33(1):163-6.
A slow-release formulation of 40 mg furosemide as capsules (Eutensin) was investigated for its pharmacokinetic and pharmacodynamic properties in comparison with conventional tablets containing 40 mg furosemide (Lasix) in a single-blind clinical pharmacological trial in 6 healthy subjects. The following results were obtained: 1. The AUC0-24 after the administration of slow-release (SR) furosemide was about 42% of that after furosemide tablets. 2. Urine volume and urinary excretion of Na and Cl were significantly greater after furosemide tablets than after SR furosemide during the first 10 h after administration. No significant difference was observed between the two formulations in the urinary excretion of K, creatinine and uric acid. No significant difference was noted in every tested pharmacodynamic parameter during the cumulative 24 h after administration. It was concluded that SR furosemide may be used in the treatment of hypertension due to its characteristics of a slow-release diuretic feature, delayed peak blood concentration, delayed maximum diuretic effect and prolonged duration of action.
在一项针对6名健康受试者的单盲临床药理学试验中，研究了40毫克速尿的缓释胶囊制剂（优特喜）与含40毫克速尿的常规片剂（速尿）相比的药代动力学和药效学特性。获得了以下结果：1. 服用缓释速尿后的AUC0-24约为服用速尿片剂后的42%。2. 服用后前10小时内，速尿片剂后的尿量以及钠和氯的尿排泄量显著高于缓释速尿后的。两种制剂在钾、肌酐和尿酸的尿排泄方面未观察到显著差异。给药后累计24小时内，各项测试的药效学参数均未发现显著差异。得出的结论是，缓释速尿因其具有缓释利尿特性、血药浓度峰值延迟、最大利尿作用延迟和作用持续时间延长等特点，可用于治疗高血压。
